Effects of benoxaprofen on the binding to and inactivation of leucoattractants by human polymorphonuclear leucocytesin vitro
- 15 Downloads
Benoxaprofen was previously found to inhibit the random and leucoattractant-induced migration of human polymorphonuclear leucocytesin vitro by a pro-oxidative mechanism . In this study the effects of benoxaprofen on the binding to PMNL of the synthetic chemotactic tripeptide FMLP, on the oxidative inactivation of this leucoattractant by PMNL and on PMNL chemotaxis, chemokinesis and orientation in an FMLP gradient have been investigated. At concentrations of 10−5M (3 μg/ml) benoxaprofen inhibited PMNL random and leucoattractant-induced migration and increased PMNL membraneassociated oxidative metabolism and cellular auto-oxidation. These effects of benoxaprofen on PMNL migration and auto-oxidation were prevented by the anti-oxidant cysteine (10−3M). Benoxaprofen inhibited both FMLP-induced chemotaxis and chemokinesis but did not affect the binding of radiolabelled FMLP to PMNL or orientation of the cells in a positive gradient of the leucoattractant. Benoxaprofen at concentrations of 5×10−5M significantly increased the oxidative inactivation of FMLP by PMNL. Inhibition of PMNL migration by benoxaprofen is mediated by the two different pro-oxidative mechanisms, viz. a cell-directed auto-oxidative mechanism and potentiation of the oxidative inactivation of leucoattractants by PMNL.
KeywordsCysteine Oxidative Metabolism Positive Gradient Benoxaprofen Oxidative Inactivation
Unable to display preview. Download preview PDF.
- C.H. Cashen, W. Dawson andE.A. Kitchen,The pharmacology of benoxaprofen 2-(4-chorophenyl)-α-methyl-5-benoxazole acetic acid, LCRL 3794 a new compound with anti-inflammatory activity apparently unrelated to inhibition of prostaglandin synthesis, J. Pharm. Pharmac.29, 330–336 (1977).Google Scholar
- S.C.R. Meacock, G.W. Civil, W. Dawson andE.A. Kitchen,Studies on leucocyte-drug interaction with benoxaprofen, Eur. J. Rheumatol. Inflammation5, 51–60 (1982).Google Scholar
- J.R. Walker andW. Dawson,Inhibition of rabbit PMN lipoxygenase activity by benoxaprofen, J. Pharm. Pharmac.31, 778–780 (1979).Google Scholar
- J.R. Walker, J.C. Boot, B. Cox andW. Dawson,Inhibition of the release of slow-reacting substance of anaphylaxis by inhibitors of lipoxygenase activity, J. Pharm. Pharmac.32 866–867 (1980).Google Scholar
- S.C.R. Meacock andE.A. Kitchen,Effects of the non-steroidal anti-inflammatory drug benoxaprofen on leucocyte migration, J. Pharm. Pharmac.31, 336–370 (1979).Google Scholar
- A. Kamal andI.M. Koch,Pharmacokinetic studies of benoxaprofen in geriatric patients, Eur. J. Rheumatol. Inflammation5, 76–81 (1982).Google Scholar
- R.C. Prokesch andW.L. Hand,Antibiotic entry into human polymorphonuclear leukocytes, Antimicrob. Ag. Chemother.21, 373–380 (1982).Google Scholar
- A.S. Ridolfo, R. Nickander andW.M. Mikulaschek,Fenoprofen and benoxaprofen, Clinics in Rheumatic Diseases5, 393–410 (1979).Google Scholar
- J. Ferguson, H.A. Addo, P.E. McGill, K.R. Woodcock, B.E. Johnson andW. Frain-Bell,A study of benoxaprofen-induced photosensitivity, Br. J. Derm.107, 429–442 (1982).Google Scholar
- M. Shadworth,Side effects of benoxaprofen, Br. med. J.285, 136 (1982).Google Scholar
- B.R. Allen,Benoxaprofen and the skin, Br. J. Derm.109, 361–364 (1983).Google Scholar